Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond M, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American pathologists clinical practice guideline focused update summary. J Oncol Pract. 2018;14(7):437–441. doi:10.1200/JOP.18.00206
   PubMed Web of Science ®Google Scholar
• Cherifi F, Da Silva A, Johnson A, et al. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer. BMC Cancer. 2022;22(1):1081. doi:10.1186/s12885-022-10163-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. 2022;35(8):1075–1082. doi:10.1038/s41379-022-01019-5
   PubMed Web of Science ®Google Scholar
• Tarantino P, Hamilton E, Tolaney SM, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962. doi:10.1200/JCO.19.02488
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study. J Clin Oncol. 2020;38(17):1887–1896. doi:10.1200/JCO.19.02318
   PubMed Web of Science ®Google Scholar
• Xu H, Han Y, Wu Y, et al. Clinicopathological characteristics and prognosis of HER2-low early-stage breast cancer: a single-institution experience. Front Oncol. 2022;12:906011. doi:10.3389/fonc.2022.906011
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu T, Kuang X, et al. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. Breast. 2022;67:1–7. doi:10.1016/j.breast.2022.12.006
   PubMed Web of Science ®Google Scholar
• Tang L, Li Z, Jiang L, Shu X, Xu Y, Liu S. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: a real-world retrospective study. Front Oncol. 2022;12:999716. doi:10.3389/fonc.2022.999716
   PubMedGoogle Scholar
• de Moura Leite L, Cesca MG, Tavares MC, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021;190(1):155–163. doi:10.1007/s10549-021-06365-7
   PubMed Web of Science ®Google Scholar
• Li JJ, Yu Y, Ge J. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer. 2023;30(3):364–378. doi:10.1007/s12282-022-01431-4
   PubMed Web of Science ®Google Scholar
• Alves FR, Gil L, Vasconcelos de Matos L, et al. Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer. Cureus. 2022;14(2):e22330.
   PubMed Web of Science ®Google Scholar
• Kang S, Lee SH, Lee HJ, et al. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer. 2022;176:30–40. doi:10.1016/j.ejca.2022.08.031
   PubMed Web of Science ®Google Scholar
• Wang W, Zhu T, Chen H, Yao Y. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer. Clin Transl Oncol. 2022. doi:10.1007/s12094-022-03062-9
   Web of Science ®Google Scholar
• Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. doi:10.6004/jnccn.2022.0030
   PubMed Web of Science ®Google Scholar
• Li JB, Jiang ZF. 李健斌, 江泽飞. 2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读 [Chinese society of clinical oncology breast cancer guideline version 2021: updates and interpretations]. Zhonghua Yi Xue Za Zhi. 2021;101(24):1835–1838. Chinese. doi:10.3760/cma.j.cn112137-20210421-00954
   PubMedGoogle Scholar
• Korde LA, Somerfield MR, Carey LA, et al. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021;39(13):1485–1505. doi:10.1200/JCO.20.03399
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond M, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond M, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364–1382. doi:10.5858/arpa.2018-0902-SA
   PubMed Web of Science ®Google Scholar
• Banerji U, van Herpen C, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a Phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(8):1124–1135. doi:10.1016/S1470-2045(19)30328-6
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38(5):444–453. doi:10.1200/JCO.19.01455
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–1161. doi:10.1016/S1470-2045(21)00301-6
   PubMed Web of Science ®Google Scholar
• Won HS, Ahn J, Kim Y, et al. Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society. Breast Cancer Res. 2022;24(1):22. doi:10.1186/s13058-022-01519-x
   PubMed Web of Science ®Google Scholar
• Tan R, Ong WS, Lee KH, et al. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022;20(1):105. doi:10.1186/s12916-022-02284-6
   PubMed Web of Science ®Google Scholar
• Ergun Y, Ucar G, Akagunduz B. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2023;115:102538. doi:10.1016/j.ctrv.2023.102538
   PubMed Web of Science ®Google Scholar
• Zhang Y, Leonard M, Shu Y, et al. Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNA nanoparticles. ACS Nano. 2017;11(1):335–346. doi:10.1021/acsnano.6b05910
   PubMed Web of Science ®Google Scholar
• Yang Y, Leonard M, Zhang Y, et al. HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1. Cancer Res. 2018;78(2):422–435. doi:10.1158/0008-5472.CAN-17-1533
   PubMed Web of Science ®Google Scholar
• de Groot S, Charehbili A, van Laarhoven HW, et al. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res. 2016;18(1):3. doi:10.1186/s13058-015-0663-3
   PubMedGoogle Scholar
• Cortellino S, Turner D, Masciullo V, et al. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci USA. 2003;100(25):15071–15076. doi:10.1073/pnas.2334585100
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Cicchillitti L, Schepis F, et al. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc Natl Acad Sci USA. 1999;96(7):3969–3974. doi:10.1073/pnas.96.7.3969
   PubMed Web of Science ®Google Scholar
• Topping RP, Wilkinson JC, Scarpinato KD. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem. 2009;284(21):14029–14039. doi:10.1074/jbc.M809303200
   PubMed Web of Science ®Google Scholar